-
Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib
•
Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase I study ‘KN-8701’, focusing on its Category 1 drug exarafenib (KIN-2787) in the Chinese mainland. This milestone comes shortly after Kinnate Biopharma Inc. (Nasdaq: KNTE) acquired an ownership stake in Kinnjiu Bio, previously held by…
